Biogen names new CFO, CMO

Michael McDonnell will retire as EVP and CFO of Biogen Inc. (NASDAQ:BIIB), a role he’s held since 2020, at the end of February. He will be succeeded by Chief Accounting Officer Robin Kramer. Biogen’s C-suite is also getting a new CMO and head of medical affairs, with Daniel Quirk named to the position. Quirk was SVP of worldwide medical affairs for immunology and neuroscience at Bristol Myers Squibb Co. (NYSE:BMY).

Medicxi-backed  Ottimo Pharma Ltd. named David Epstein chair and CEO, Mehdi Shahidi CMO and head of development, and James Sabry vice chair. Epstein was CEO and a board member of Seagen Inc., and Shahidi was SVP, CMO and global head of medicine at Boehringer Ingelheim GmbH. Sabry, who recently spoke with BioCentury about industry-shaping trends, is EVP, CBO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Ottimo is developing jankistomig, a PD1xVEGFR2 antibody for cancer...